Posterior Reversible Encephalopathy Syndrome in Early‐Stage Breast Cancer

Wider use of chemotherapy and targeted agents can be associated with posterior reversible encephalopathy syndrome (PRES). This syndrome is most commonly found in metastatic adenocarcinoma treated with platinum‐based analogs and is managed with cessation of the precipitating medication. We present the first case of PRES in early‐stage breast cancer and discuss the further management of this condition. Recognition of this condition and correction of identifiable precipitating factor including cessation of relevant medications remains important in its management.